PARP1 was proposed as a new treatment for cancer, as the synthetic lethality concept suggested that its depletion in breast-cancer patients with germline mutations in the BRCA1 or BRCA2 genes, key molecules in the homologous recombination (HR) pathway, could cause cancer cell death [7,8]. Here, BRCA2 is linked to breast carcinoma.